Governance Immatics N.V.

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-15 pm EDT			5-day change	1st Jan Change
9.470 ^USD	+1.28%		-5.11%	-9.81%

Jun. 01	Immatics N.V. Announces Updated Clinical Data For IMA203CD8, IMA401, And Anzu-Cel PRAME Cell Therapies	CI
Jun. 01	Immatics Presents Clinical Activity and Response Dynamics of Anzu-Cel Prame Cell Therapy At 2026 Asco Annual Meeting	CI

Executive Committee: Immatics N.V.

Manager

Positions heldSince

Harpreet Singh-Jasuja

51 year

Chief Executive Officer	2018-12-31
Founder	1999-12-31

Ephraim Hofsäß

Comptroller/Controller/Auditor

2019-11-30

Amie Krause

53 year

Human Resources Officer

2025-10-26

Venkat Ramanan

57 year

Director of Finance/CFO

2025-09-30

Liane Preussner

Chief Tech/Sci/R&D Officer

2024-12-31

Laurens Schröder

36 year

Sales & Marketing

2024-07-31

Jürgen Richert

Chief Tech/Sci/R&D Officer

2024-12-31

John Hermanek

General Counsel

2025-03-31

Tamara Louw

Human Resources Officer

2021-07-31

Miriam Meyer

General Counsel

2009-08-31

Cedrik M. Britten

51 year

Chief Tech/Sci/R&D Officer

2020-05-31

Edward Sturchio

50 year

General Counsel

2020-05-31

Jordan Silverstein

46 year

Investor Relations Contact

2019-08-31

Steffen Walter

49 year

Chief Operating Officer

2023-03-20

Composition of the Board of Directors: Immatics N.V.

Director

CommitteesSince

Peter Chambré

70 year

Governance Committee Chair	2020-06-30
Nominating Committee Chair	2020-06-30

Adam Stone

46 year

Audit Committee
Governance Committee Chair	2015-10-31
Nominating Committee Chair	2015-10-31
Compensation Committee	2020-06-30
Governance Committee	2020-06-30
Nominating Committee	2020-06-30

Heather Mason

66 year

Audit Committee	2020-06-30
Nominating Committee	2020-08-31
Compensation Committee	2020-06-30

Eliot Forster

60 year

Audit Committee	2020-09-14
Governance Committee	2020-09-14
Nominating Committee	2023-09-13

Mathias Hothum

58 year

Compensation Committee	2023-06-19
Nominating Committee	2020-08-17
Governance Committee	2020-08-17

Michael Atieh

72 year

Finance Committee	1989-12-31
Audit Committee Chair	2020-06-30

Paul Carter

66 year

Audit Committee	2020-06-30
Compensation Committee Chair	2020-06-30

Alise Reicin

65 year

Compensation Committee	2021-04-21
HR Committee

Harpreet Singh-Jasuja

51 year

Director/Board Member

2020-06-30

Latest Appointments: Immatics N.V.

25-10-27	Immatics N.V. Appoints Amie Krause as Chief People Officer, Effective October 27, 2025	CI
25-10-01	Immatics Names Venkat Ramanan CFO	MT
24-10-11	Exchange-Traded Funds Down, Equity Futures Mixed Pre-Bell Friday as Investors Gear Up for Earnings Season	MT
24-07-31	Immatics N.V. Appoints Alise Reicin to Board of Directors	CI
23-06-20	Immatics N.V. Appoints M.P. Hothum as Non-Executive Director Class III	CI
20-09-15	Immatics N.V. Appoints Biotech Executive Eliot Forster to Board of Directors	CI
20-06-04	Immatics Biotechnologies Gmbh Announces Management Changes	CI

More news

Former Officers and Directors: Immatics N.V.

Insider

Positions held

SinceUntil

Arnd Christ

Director of Finance/CFO

2020-09-30

2025-09-30

Maria Poulada

Comptroller/Controller/Auditor

2012-12-31

2024-05-31

Evelyn Roth-Geissler

Chief Tech/Sci/R&D Officer

2023-09-30

Nancy Valente

Director/Board Member

2022-03-21

2023-05-11

Christof Hettich

Director/Board Member

2005-12-31

2021-06-16

Friedrich von Bohlen und Halbach

Director/Board Member	2005-12-31	2019-12-31
Director/Board Member	2021-06-16	2023-06-19

Daniel Lübberstedt

Chief Tech/Sci/R&D Officer

2019-09-30

Anja Heuer

Public Communications Contact

2019-04-30

Jessica Mosby

Chief Administrative Officer	2017-08-31	-
Chief Operating Officer	2017-08-31	-

Thomas Ulmer

Director of Finance/CFO

2020-06-30

Rebecca Griffith Eskew

Chief Tech/Sci/R&D Officer

Age distribution of managers

Parity Men Women

Male	23
Female	5

Of which Executive Committee

Male	12
Female	2

Of which Directors

Male	8
Female	1

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Employees

678

Sector

Biotechnology & Medical Research

More about the company